MedTrace Logo

Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers

NCT01436695 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2011-09-20

No results posted yet for this study

Summary

Epilepsy is a syndrome of episodic brain dysfunction characterized by recurrent seemingly unpredictable spontaneous seizures. The occurrence of the seizure in patients without any forewarning is the most debilitating aspect of the disease.

The Epicall system is intended for early detection of seizure related life threatening events by monitoring per-seizures biomarkers. The system is based on a sticker placed on the side of the face. The external sticker incorporates EOG (electrooculograph electrode) and PPG (photoplethysmograph electrode) sensors for continuous monitoring of:

1. Heart Rate (base line, increase, decrease, asystole).
2. Extra ocular eye movement (blinking, eye deviation, roving eye movements).

Conditions

  • Seizure

Interventions

DEVICE

Epicall

The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.

Sponsors & Collaborators

  • Epicall LTD

    lead INDUSTRY

Principal Investigators

  • Eli Heyman, Dr · Asaf-Harofeh Medical Center, Zrifin Israel

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-06-30

Countries

  • Israel

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01436695 on ClinicalTrials.gov